The Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer) is a multidisciplinary oncology summit focused on novel therapeutics, precision medicine, and biomarker-driven innovation. Featuring leaders in translational research and clinical oncology, the program bridges early-phase science with real-world patient care through expert lectures and interactive case discussions.
Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.
| Friday, August 7, 2026 | |
|---|---|
| 7:00am | Check-in and Breakfast in Exhibit Hall |
| 8:00am | Horizon CME App Overview and CE Housekeeping |
| 8:10am | Welcome and Introductions |
| Block One: TBA | |
| 8:15am | (01) The Daniel D. Von Hoff Keynote Lecture: TBD » TBA |
| 9:15am | Break – Refreshments in the Exhibit Hall |
| Block Two: Small Molecules and Targeted Therapy | |
| 9:40am | (02) New Combinations in the Treatment of PRMT5 Inhibitors » TBA |
| 10:00am | (03) FAK inhibitors in Ovarian Cancer » TBA |
| 10:20am | (04) Emerging Novel TP53 Targeted Drugs » Alison Schram, MD – Associate Attending Physician | Section Head, Oral Therapeutics | Early Drug Development and Gynecologic Medical Oncology Services | Department of Medicine, Division of Medical Oncology | Memorial Sloan Kettering Cancer Center | New York, NY |
| 10:40am | (05) Q+A Panel and Discussion: Block Two » Faculty for Sessions 02 – 04 |
| 11:00am | Gather Lunch |
| 11:10am | Lunch |
| 11:55am | Dessert – Refreshments in Exhibit Hall |
| Block Three: Development of ADCs in Solid Tumors | |
| 12:10pm | (06) Development of ADCs in Lung Cancer » TBA |
| 12:30pm | (07) ADCs in GU Malignancies » TBA |
| 12:50pm | (08) Q+A Panel and Discussion: Block Three » Faculty for Sessions 06 – 07 |
| 1:10pm | Message from the Cancer Charities |
| 1:25pm | Break – Trivia for Charity in the Exhibit Hall |
| Block Four: Recent Precision Medicine Advances in Hematology/Oncology | |
| 1:45pm | (09) Lung Cancers » TBA |
| 2:05pm | (10) Breast Cancers » Antonio Giordano, MD, PhD – Medical Oncologist | Clinical Director Center for Cancer Therapeutic Innovations | Dana-Farber Cancer Institute | Boston, MA |
| 2:25pm | (11) GI Cancers » Eileen M. O’Reilly, MD – Medical Oncologist | Memorial Sloan Kettering Cancer Center | New York, NY |
| 2:45pm | (12) MPNs » TBA |
| 3:05pm | (13) Q+A Panel and Discussion: Block Four » Faculty from Sessions 09 – 12 |
| 3:25pm | Break – Refreshments in the Exhibit Hall |
| Block Five: Clinical Advances in RAS Targeting | |
| 3:50pm | (14) Updates on RAS ON Inhibitors » TBA |
| 4:10pm | (15) RAS Protacs and Molecular Glues » TBA |
| 4:30pm | (16) Allosteric RAS inhibitors » TBA |
| 4:50pm | (17) Q+A Panel and Discussion: Block Five » Faculty from Sessions 14 – 16 |
| 5:10pm | Networking Reception – Exhibit Hall |
| Saturday, August 8, 2026 | |
| 7:00am | Check-in & Breakfast available in Exhibit Hall |
| 7:55am | Horizon CME App Overview and CE Housekeeping |
| 8:00am | Welcome and Introductions |
| Block Six: Biomarker Methodology in Cancer | |
| 8:10am | (18) ctDNA Applications in Management of Patients With Advanced Stage Colorectal Cancer » Cathy Eng, MD – Professor of Medicine | Co-Leader, VICC Gastrointestinal Cancer Research Program | David H. Johnson Chair in Surgical and Medical Oncology | Co-Director, GI Oncology | Director, VICC Young Adults Program | Co-Chair, NCI Gastrointestinal Steering Committee | Vanderbilt University Medical Center | Nashville, TN |
| 8:30am | Gather for Breakfast |
| 8:35am | Non-CME Breakfast Symposium Sponsored by TBA » TBA |
| 9:20am | Transition Break |
| 9:25am | (19) Multi-Modal Genomic Integration » TBA |
| 9:45am | (20) Tumor Agnostic Therapies: Where Have We Been and Where are We Headed? » Vivek Subbiah, MD – Inaugural Associate Director, Drug Development and Precision Oncology | Stanford Cancer Institute | Palo Alto, CA |
| 10:05am | (21) Digital Biomarkers in Early Phase Clinical Trials with a Focus in Decentralized Clinical Trials » TBA |
| 10:25am | (22) Q+A Panel and Discussion: Block Six » Faculty for Sessions 18- 21 |
| 10:45am | Break – Refreshments in the Exhibit Hall + Poster Session |
| Block Seven: Clinical Trial Methodology | |
| 11:50am | (23) Bringing Trials to patients, Evolution and Progress of CCBW in Clinical Trials » TBA |
| 12:10pm | (24) Novel Endpoints for Therapeutic Response in Early Phase Trials » TBA |
| 12:30pm | (25) Statistical Trial Design for Early Phase Clinical Trials » TBA |
| 12:50pm | (26) Role of Patient Advocacy in Early Phase Trials » TBA |
| 1:10pm | (27) Q+A Panel and Discussion: Block Seven » Faculty from Sessions 23 – 26 |
| 1:30pm | Gather for Lunch |
| 1:35pm | Buffet Lunch / Non-CME/CE Presentation Sponsored by TBA » TBA |
| 2:20pm | Dessert Break in the Exhibit Hall |
| Block Eight: Immunotherapy, Radiopharnaecuticals, and Advanced Delivery Devices in Solid Tumors | |
| 2:35pm | (28) Innovations in Alpha Emitter Therapeutics in Prostate Cancer » Ulka Vaishampayan, MD – Professor of Internal Medicine, Director of Phase 1 Program, Co-Leader of the Translational and Clinical Research Program | University of Michigan, Rogel Cancer Center | Ann Arbor, MI |
| 2:55pm | (29) Innovations in HER2 Targeted Therapy » Ghassan K. Abou-Alfa, MD, MBA – Medical Oncologist | Memorial Sloan Kettering Cancer Center | New York, NY |
| 3:15pm | Break – Refreshments in the Exhibit Hall |
| 3:35pm | (30) Clinical Advances in ADC Development and Novel Payloads » Daruka Mahadevan, MD, PhD – Professor of Medicine | Division of Hematology/Medical Oncology | Director of Research, Multispecialty Research Hospital | AT&T President’s Distinguished University Chair | Director, Institute for Drug Development | Associate Director Clinical Research | Mays Cancer Center, University of Texas Health | San Antonio, TX |
| 3:55pm | (31) A Novel Therapuetic Modality, Tumor Treating Fields in Pancreatic Cancer » Hani Babiker, MD – Associate Professor of Medicine, Pancreaticobiliary, GI Oncology, Early Phase Therapeutics, and Consultant | Mayo Clinic | Jacksonville, FL |
| 4:15pm | (32) Q+A Panel and Discussion: Block Eight » Faculty for Sessions 28- 31 |
| 4:35pm | Closing Comments |
The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This conference is approved for up to 12.00 credit by the Washington State Pharmacy Association.
This activity is approved for up to 12.00 credit by the Washington State Pharmacy Association. Activity Type: Live| Start/End date: Fri, 08/07/2026 – 7:00am-Sat, 08/08/2026 – 5:15pm The Washington State Pharmacy Association (WSPA) is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. NOTE FOR PHARMACISTS: It is the responsibility of the pharmacist or pharmacy technician to provide the correct information [NABP eProfile ID and DOB (in MMDD format)] within the evaluation, in order to receive credit for participating in this CPE activity. Following the activity’s end date, there is a maximum of 60 days allowed to upload the CPE information to the CPE Monitor. WSPA will upload the CPE information to the CPE monitor 50 days after the activity – please check your CPE Monitor at this time to ensure the CPE is uploaded in your profile. If you encounter any CPE problems, please contact WSPA at 425- 228-7171
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this Live activity for a maximum of 12.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This nursing continuing professional development activity was approved by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center’s Commission on Accreditation.Upon completion, NPs and RNs will be awarded up to 12.00 credit.
This nursing continuing professional development activity was approved by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center’s Commission on Accreditation.Upon completion, NPs and RNs will be awarded up to 4.50 credit.
Associate Professor of Medicine, Pancreaticobiliary, GI Oncology, Early Phase Therapeutics, and Consultant Mayo Clinic Jacksonville, FL
COURSE DIRECTOR
Professor of Medicine Mayo Clinic, College of Medicine and Science Phoenix, AZ
CO-DIRECTOR
Chief, Leukemia Service Director, Program for Drug Development in Leukemia, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
CHAIR
Director - Research Unit for Molecular Therapy of Cancer, UITM – “CaixaResearch” (VHIO, Barcelona) Co-Director - Clinical Research Program (VHIO, Barcelona) Group Leader - Early Drug Development (VHIO, Barcelona) Medical Oncologist (HUVH, Barcelona) Director - Phase I Unit (NEXT Oncology, Barcelona) Barcelona, Spain
CHAIR
Medical Oncologist, CEO and Founder of NEXT Oncology Texas Oncology-San Antonio Babcock Next Oncology San Antonio, TX
CHAIR
We want to ensure that your time at the 2026 STOP Cancer conference is convenient and memorable. Staying at our host hotel provides a hassle-free experience and puts you at the heart of the activity surrounding the conference.
Overnight Accommodations:
Dates for discounted rates: August 6-8, 2026
Discounted Booking Deadline: July 4, 2026
Click here to book your room today!
Room rate: $359
Parking: Complimentary parking
All reservations must be booked using the link above before the closing date listed. Overnight accommodation, parking, and resort fees will revert back to standard hotel pricing outside of the dates above. A set number of rooms have been blocked off for the discounted pricing. If all of those rooms have already been booked, discounted pricing may not be available for additional rooms or accommodations.
Professor of Medicine and of Pediatrics, Division of Oncology Stanford University School of Medicine Associate Director, Drug Development & Precision Oncology Stanford Cancer Institute Executive Medical Director, Novel Therapies & Clinical Trial Network Stanford Health Care Palo Alto, CA
CHAIR